Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
10.1097/JTO.0b013e3181dd1386
Saved in:
Main Authors: | Yeo, W.-L., Lau, M.W., Warner, J.L., Bodio, K., Huberman, M.S., Tenen, D.G., Kobayashi, S., Costa, D.B., Riely, G.J., Kris, M.G., Yeap, B.Y., Pao, W. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
2011
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/27135 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014) -
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014) -
EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020) -
Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019) -
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022)